Physician profile
Paul M Popper
NPI 1124045216
$9,058.93
in general payments reported to CMS, 2019-2025
33 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $586 · 2021: $1,169 · 2022: $1,479 · 2023: $1,048 · 2024: $1,556 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,708.10 | 2019-2025 | Biomonitor, Amvia Edge, Selectra |
| Abbott Laboratories | $989.28 | 2019-2025 | Mitraclip, Jot Dx, Gallant |
| Bayer Healthcare Pharmaceuticals INC. | $931.02 | 2021-2025 | |
| Cvrx, INC. | $908.93 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $646.24 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Amgen INC. | $491.17 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $468.22 | 2019-2025 | Farapulse |
| E.R. Squibb & Sons, L.L.C. | $359.33 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.63 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $263.11 | 2019-2025 | |
| Philips North America LLC | $210.63 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $186.21 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.13 | 2019-2025 | Lifevest |
| Heartflow, INC. | $173.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $131.46 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.26 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $101.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $100.36 | 2019-2024 | Farxiga |
| Coala Life INC | $93.20 | 2021 | |
| Impulse Dynamics (USA) INC. | $80.35 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $76.80 | 2024 | Arcalyst |
| Braemar Manufacturing, LLC | $70.27 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $64.17 | 2024 | |
| Scpharmaceuticals INC. | $52.34 | 2024-2025 | |
| Esperion Therapeutics, INC. | $48.83 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $42.24 | 2022-2024 | Onpattro |
| Amarin Pharma, INC. | $40.63 | 2020-2021 | |
| Abiomed | $40.14 | 2025 | |
| Medtronic Vascular, INC. | $36.53 | 2019 | |
| Kestra Medical Technology Services, INC. | $28.55 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $28.25 | 2023 | Opsumit, Uptravi |
| G Medical Diagnostic Services, INC. | $28.16 | 2019-2022 | |
| Novo Nordisk INC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Popper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.